ALFA Finder| Execution period | 60 months |
|---|
NSE filing, NSE: ALKEM. Summary written from the filing by ALFA Finder's alert engine.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,218.00
- Market cap
- ₹62,389 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 28.9×Sector 43.8×
- Promoter holding
- 49.70%+0.00% QoQ
- FII holding
- 10.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Results Update
Alkem posted Q2FY27 revenue of ₹4,552 Cr, up 14% YoY, with 22.5% EBITDA margin. Net profit fell 11.7% to ₹675 Cr on higher R&D.
Alkem Laboratories Management Change
Alkem Laboratories appointed Mr. Gopal Kothari as CFO and Key Managerial Personnel effective 2 December 2026. The 24-year finance veteran is a CA and CS.
Alkem Laboratories Q2 FY27 Results: Net Profit ₹667.1 Cr, Down 14.4% YoY
Alkem Laboratories Ltd reported revenue from operations of ₹4,552 Cr (+13.8% YoY) and net profit of ₹667.1 Cr (-14.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹667.1 Cr · -14.4% YoY
Alkem Laboratories Merger & Restructuring Worth ₹9.56 Cr
Alkem incorporated a Saudi Arabian joint venture subsidiary, Alkem Pharma Company LLC, on 8 November 2026. It holds 51% after subscribing SAR 38.25 lakh, about ₹9.56 Crore.
- Value
- ₹9.56 Cr
Alkem Laboratories Board Meeting Date
Alkem Laboratories has scheduled its Board meeting for 12 Nov 2026 to consider Q2 and H1 FY27 unaudited results. No financial figures are disclosed in this advance notice.
Alkem Laboratories Management Change
Alkem Laboratories appointed Dr. Amrut Naik as CEO effective November 11, 2026. The Board designated him as Key Managerial Personnel at its November 3 meeting.
Other board meeting outcome announcements
All →Ennature Bio Pharma Board Meeting Outcome
Ennature Bio Pharma's board approved adoption of new Articles of Association to align with SCRA Rules 1957 and group governance. The change is subject to shareholder approval.
Shri Keshav Cements & Infra Board Meeting Outcome
Shri Keshav Cements' board approved un-audited financial and segment-wise revenue results for the quarter and half-year ended 30 September 2026. No other material decisions were transacted.
Balmer Lawrie Investments Board Meeting Outcome
Balmer Lawrie Investments appointed M/s. K. K. Chanani & Associates as Statutory Auditor for FY 2026-27 under Section 139(5), per a C&AG letter. The appointment is effective from 10 November 2026.
- Execution
- FY 2026-27
Jiwanram Sheoduttrai Industries Board Meeting Outcome
Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.
Finolex Cables Board Meeting Outcome
Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).
Chatterbox Technologies Board Meeting Outcome
Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.